Matt Galloway, host of CBC's Metro Morning, spoke to Prateek Dwivedi, vice-president and chief information officer at Mount Sinai Hospital, about VitalHub's technology.
Dwivedi's interview with Galloway is no longer publicly available.
Dwivedi and Galloway touch on various product highlights, including:
Longitudinal view of a patient's history and benefits of having access to that information when making rounds or walking between locations.
Security concerns, including encryption, that are equivalent to those used in the hospital.
Feedback from doctors, nurses and others who have used the product.
TORONTO, ON (Jan. 25, 2011) —Doctors, nurses and administrators can now access electronic health applications on mobile, hand-held technology through VitalHub Corp..
The unique start-up company was spun-off from mobile health technologies developed Toronto's Mount Sinai Hospital, thanks in part to $300,000 in seed financing from MaRS Innovation that will give it a crucial head start in the fiercely competitive mobile IT health sector.
MaRS Innovation invests in the most commercially promising discoveries emerging from its member institutions, which include 16 of Toronto's ...
TORONTO (March 2, 2010) – MaRS Innovation is delighted to announce that two of its commercialization projects – notably an umbilical cord stem cell technology from Mount Sinai Hospital and nicotine addiction therapy from the Centre for Addiction and Mental Health (CAMH) - have received Canadian Institutes of Health Research (CIHR) Proof of Principle (PoP) funding.
This funding – each grant is valued at $150,000 – is third party validation of MaRS Innovation’s approach to commercializing its members’ discoveries. The CIHR performs rigorous due diligence and ...
TORONTO (June 29, 2009) – MaRS Innovation and the Samuel Lunenfeld Research Institute of Mount Sinai Hospital are pleased to announce that they have entered into an agreement to collaboratively initiate commercialization of an umbilical cord stem cell technology for potential treatment in cardiovascular disease, diabetes and neurological disorders.
“With the Toronto area identified as a world-leading cluster in stem cell research, we are extremely excited to have identified this technology as our first commercialization opportunity,” said Dr. Raphael (Rafi) Hofstein, President ...